NCT02321540 - A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

September 16, 2021

Study Completion Date

September 16, 2021

Conditions

Lung Cancer

Interventions

DRUG

Ibrutinib

"Part 1 Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle.~Part 2 Starting level of Ibrutinib: Maximum tolerated dose from Part 1 or 840 mg daily."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston